The private placement is anticipated to close on or about March 30, 2026, subject to the satisfaction of customary closing conditions. Upon closing, Vor Biopharma will have a total of 54,185,582 shares of common stock outstanding. The company plans to utilize the net proceeds from this placement to advance the development of its clinical pipeline, particularly focusing on its lead candidate, telitacicept, which is currently undergoing Phase 3 clinical trials for conditions such as generalized myasthenia gravis and primary Sjögren’s disease.
Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of Vor Biopharma, expressed optimism regarding the financing, stating, "BAFF/APRIL inhibition represents one of the next major waves of innovation in autoimmune disease, and telitacicept is at the forefront of the field. This financing enables us to accelerate our efforts in generalized myasthenia gravis and advance primary Sjögren’s disease as a key next frontier."
The company also entered into a Registration Rights Agreement with the investors, obligating it to file a registration statement with the SEC to register the resale of the shares within 30 days of the closing date. This agreement includes provisions for liquidated damages payable to the investors if the company fails to meet certain filing or effectiveness deadlines.
Vor Biopharma's strategic focus on telitacicept, which has shown promising Phase 3 data across multiple indications, positions the company well in a market with significant unmet needs. The investment from TCGX reflects a strong belief in the potential of telitacicept to become a foundational therapy for multiple B-cell mediated diseases. As Vor Biopharma continues to advance its clinical programs, this funding will be crucial in driving long-term value for shareholders and improving treatment options for patients suffering from autoimmune diseases.
